Survodutide (Dual Glucagon/GLP-1 Receptor Agonist) – BI 456906

Product Overview

Survodutide is a breakthrough, long-acting dual agonist peptide engineered to simultaneously activate the glucagon receptor (GCGR) and the glucagon-like peptide-1 (GLP-1) receptor. This dual-action mechanism is specifically designed to provide a synergistic metabolic effect: while the GLP-1 receptor component provides potent appetite suppression and insulin regulation, the glucagon receptor agonism directly increases total energy expenditure and promotes hepatic lipid oxidation. Survodutide represents a premier research compound for studying profound weight management, hepatic steatosis (MASH/NASH) reversal, and the optimization of metabolic homeostasis.

Technical Specifications

• Molecular Formula: C192H289N47O61

• Molecular Weight: 4231.63 g/mol

• CAS Number: 2805997-46-8

• Receptor Profile: Dual Agonist (Glucagon Receptor + GLP-1 Receptor)

Mechanism of Action

Survodutide engages two distinct physiological systems to deliver comprehensive metabolic control:

• GLP-1 Receptor Agonism: Stimulates glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and activates central hypothalamic satiety pathways to drastically reduce food intake.

• Glucagon Receptor Agonism (GCGR): Directly stimulates hepatic glycogenolysis and gluconeogenesis, increases total energy expenditure through thermogenic pathways (including brown adipose tissue activation), and actively promotes hepatic lipid oxidation.

• Direct Hepatic Efficacy: The inclusion of GCGR agonism provides a distinct mechanistic advantage over pure GLP-1 agonists; it directly targets the liver to reduce de novo lipogenesis and fat accumulation, potentially improving fibrosis and steatosis independently of total weight loss.

• Glycemic Homeostasis: The optimized ratio of GLP-1/GCGR activity ensures that the potential hyperglycemic effects of glucagon are fully offset by the insulinotropic effects of GLP-1, resulting in a net improvement in glucose tolerance.

Primary Research Applications

Survodutide is a critical compound for in vitro and animal model studies investigating:

• Advanced Obesity and Chronic Weight Management Models

• Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) and Fibrosis

• Hepatic Lipid Oxidation and De Novo Lipogenesis Suppression

• Energy Expenditure Optimization and Basal Metabolic Rate (BMR) Enhancement

• Cardiovascular Risk Factor Modification and Metabolic Syndrome

Storage & Handling

For optimal long-term stability, store unopened vials strictly refrigerated at 36°F to 46°F (2°C to 8°C). Do not freeze. Protect strictly from light. Once reconstituted, ensure the solution remains refrigerated and utilized in accordance with laboratory-validated timelines to maintain the integrity of the dual-agonist structure.

⚠️ Important Disclaimer for Carbon Nova Labs Customers: All information provided is for educational and reference purposes only. Survodutide is sold strictly for laboratory research use only. This compound is not approved by the FDA for human consumption, therapeutic use, or clinical application. Ensure compliance with all institutional safety protocols and consult qualified professionals before conducting research.